Hearing loss, autosomal recessive
MONDO:0019588Autosomal recessive form of nonsyndromic deafness.
Also known as: hearing loss, autosomal recessive, autosomal recessive isolated neurosensory deafness type DFNB, autosomal recessive isolated sensorineural deafness type DFNB, autosomal recessive non-syndromic neurosensory deafness type DFNB, autosomal recessive non-syndromic sensorineural deafness type DFNB, autosomal recessive nonsyndromic deafness, autosomal recessive nonsyndromic genetic deafness, deafness, autosomal recessive
17 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Gene therapy aims to restore hearing in children born deaf
⭐️ CURE ⭐️ Recruiting nowThis study tests a new gene therapy called DB-OTO for children with hearing loss caused by changes in the otoferlin gene. The treatment is injected into the inner ear to help restore hearing. Up to 30 children and infants will take part to check safety and how well it works.
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: ⭐️ CURE ⭐️
Last updated Aug 07, 2026 00:00 UTC
-
One-time gene therapy aims to restore hearing in kids with genetic deafness
Disease control Recruiting nowThis early-stage trial tests a new gene therapy called SKY-GJB2 for children aged 9 months to 7 years with hearing loss caused by changes in the GJB2 gene. The therapy is given as a single injection into the inner ear using a special delivery device. The study will enroll 10 chil…
Phase: PHASE1, PHASE2 • Sponsor: Skylark Bio Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for hard-to-treat lung cancer: experimental drug targets MET gene
Disease control Recruiting nowThis study tests an experimental drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. About 231 participants will take part.
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy aims to restore hearing in deaf children
Disease control Recruiting nowThis trial tests a gene therapy called EHT102 for children with congenital hearing loss caused by mutations in the OTOF gene. Up to 30 children will receive a single injection in one ear to see if it safely improves hearing. The study is early-stage, focusing on safety and whethe…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Euhearing Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Gene therapy aims to restore hearing in children with rare genetic deafness
Disease control Recruiting nowThis trial tests a gene therapy called AAVAnc80-hOTOF for people with severe hearing loss caused by mutations in the otoferlin gene. The therapy is given as a single injection into the inner ear during surgery. The study will check if the treatment is safe and if it can improve h…
Phase: PHASE1, PHASE2 • Sponsor: Akouos, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Scientists track hearing loss in kids to unlock future treatments
Knowledge-focused Recruiting nowThis study follows 180 children up to age 16 who have hearing loss caused by mutations in the GJB2 or OTOF genes. Researchers will regularly measure their hearing using standard tests and questionnaires to see how it changes over time. The goal is to better understand the natural…
Sponsor: Sensorion • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists track rare genetic hearing loss over time
Knowledge-focused Recruiting nowThis study follows up to 150 people with hearing loss caused by changes in the otoferlin gene. Researchers will measure hearing function using tests like auditory brainstem response (ABR) and otoacoustic emissions (OAE). The goal is to learn how this type of hearing loss changes …
Sponsor: Akouos, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New registry aims to unlock secrets of rare genetic hearing loss
Knowledge-focused Recruiting nowThis study is building a registry of 100 people with hearing loss caused by changes in the CABP2 gene. Researchers will collect hearing test results and genetic information to learn how the condition progresses over time. The goal is to better understand the disease, not to test …
Sponsor: University Medical Center Goettingen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC